THOMSON REUTERS
CORTELLIS™

Revance Therapeutics Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 15-Dec-2014

THOMSON REUTERS
3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

Return to Table of Contents

THOMSON REUTERS

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurateand validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

Return to Table of Contents

GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Return to Table of Contents

TABLE OF CONTENTS

Company Overview..... 5
Company Profile..... 6
Product Portfolio Summary..... 7
Product Portfolio Drug Pipeline Detail..... 10
Phase 2 Clinical..... 11
Discovery..... 16

Return to Table of Contents

Revance Therapeutics Inc

COMPANY OVERVIEW

Company Name	Revance Therapeutics Inc
Parent Company Name	Revance Therapeutics Inc
Website	http://www.revance.com/
Country	US
Number of Drugs in Active Development	2
Number of Inactive Drugs	1
Number of Patents as Owner	10
Number of Patents as Third Party	0
Number of Deals	4
Key Indications	Unidentified indication,Acne,Hyperhidrosis,Migraine,Cerebral palsy,Muscle spasm,Rhinitis,Rosacea,Strabismus,Temporomandibular joint syndrome
Key Target-based Actions	Botulinum toxin A stimulator,Acetylcholine receptor antagonist,Botulinum toxin B stimulator,Botulinum toxin C1 stimulator,Botulinum toxin D stimulator,Botulinum toxin E stimulator,Botulinum toxin F stimulator,Botulinum toxin G stimulator,Botulinum toxin stimulator
Key Technologies	Toxin,Peptide,Biological therapeutic,Parenteral formulation unspecified,Dermatological formulation,Injectable formulation,Dermatological gel formulation,Freeze drying,Absorption enhancer transdermal,Drug combination,Drying,Formulation preservation,Natural product,Oligosaccharide,Patch formulation,Pharmaceutical carrier,Transdermal

COMPANY PROFILE

SUMMARY

Revance Therapeutics, headquartered in Mountain View, CA, is a privately-held biopharmaceutical company. Revance specializes in developing dermatology products using its transdermal delivery technology and tissue remodeling agents.

LICENSING AGREEMENTS

In December 2007, Medicis was to make an equity investment in Revance , as well as enter into an option agreement to acquire Revance or exclusively license North American rights to Revance's botulinum toxin type A aesthetic product. Medicis would make a $20 million investment in Revance, receiving preferred stock equivalent of almost 10%. Revance would be responsible for manufacturing worldwide, while Medicis had the right to exercise the option upon completion of certain regulatory milestones through the end of phase II development. On exercising the license option, Revance would receive an option payment, milestones and royalties. The companies also agreed to negotiate a development program for the application of Revance's drug delivery technology. In July 2009, Medicis obtained worldwide aesthetic and dermatological rights to the botulinum toxin type A product.

FINANCIAL

In June 2014, the company announced the pricing of underwritten public offering of 4 million shares priced at $30.50 each. The underwriters were granted 30-day option to purchase an additional 600,000 shares. At that time, the offering was expected to close on June 24, 2014. Later that month, the offering of 4.6 million shares was closed and the company raised net proceeds of approximately $131.3 million.

In June 2014, the company proposed an underwritten public offering of 3 million shares and expected to grant the underwriters a 30-day option to acquire an additional 450,000 shares.

In March 2014, the company was added to the Russell 2000 and Russell 3000 indexes.

In February 2014, Revance priced an initial public offering of 6 million common stock shares at a price of $16 each. The shares began trading on the NASDAQ Global Market under the ticker symbol 'RVNC'. The underwriters were granted a 30-day option to buy up to an additional 0.9 million common stock shares at the same price to cover over-allotments. At that time, the offering was expected to close on February 11, 2014. Later that month, the initial public offering of

Return to Table of Contents

6,900,000 shares of common stock was closed. The company raised gross proceeds of approximately $110 million and net proceeds of $102.7 million [1524055,.

In April 2013, the company raised $33 million from a series E growth financing and at that time, $71 million in convertible debt was converted into the series E preferred stock.

In June 2011, Revance closed $45 million financing.

In November 2008, the company secured $8 million in venture debt financing.

In May 2008, Revance raised a further $8 million from a series C financing, bringing the total raised to $51.2 million.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Return to Table of Contents

Drugs by Indication Table

Indication	Active	Inactive	Total
Inflammatory disease	0	2	2
Unidentified indication	2	0	2
Otorhinolaryngological disease	0	1	1
Respiratory disease	0	1	1
Infectious disease	0	1	1
Dermatological disease	1	0	1
Neurological disease	1	0	1
Musculoskeletal disease	0	1	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	1
No Development Reported	1

Return to Table of Contents

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	3	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Degeneration	0	2
Otorhinolaryngological disease	0	1
Immune disorder	0	1
Infectious disease	0	1
Respiratory disease	0	1
Inflammatory disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	0	2
Phase 2	0	2

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical
Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Endocrine disease	2	0	2
Gastrointestinal disease	3	0	3
Genitourinary disease	3	0	3

Return to Table of Contents

Immune disorder	3	0	3
Musculoskeletal disease	7	0	7
Neoplasm	3	0	3
Ocular disease	3	0	3
Metabolic disorder	3	0	3
Mouth disease	1	0	1
Neurological disease	6	0	6
Nutritional disorder	1	0	1
Prophylaxis	1	0	1
Respiratory disease	4	0	4
Infectious disease	6	0	6
Injury	2	0	2
Inflammatory disease	5	0	5
Otorhinolaryngological disease	4	0	4
Dermatological disease	11	0	11

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Return to Table of Contents

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

RT-001, Revance Therapeutics

RT-001, Revance Therapeutics SNAPSHOT

Drug Name	RT-001, Revance Therapeutics
Key Synonyms	
Originator Company	Revance Therapeutics Inc
Active Companies	Revance Therapeutics Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Migraine;Hyperhidrosis;Unidentified indication;Acne
Target-based Actions	Botulinum toxin A stimulator
Other Actions	Analgesic;Dermatological agent
Technologies	Dermatological formulation;Biological therapeutic;Dermatological gel formulation;Peptide;Toxin
Last Change Date	09-Apr-2014

RT-001, Revance Therapeutics DEVELOPMENT PROFILE

SUMMARY

Revance is developing RT-001, a botulinum toxin type A (BoNTA) protein, delivered using the company's TransMTS peptide technology, for the potential topical gel treatment of hyperhidrosis and chronic migraine headaches,. The company is investigating RT-001 for acne. In January 2007, data from a phase I/II hyperhidrosis study were published . In March 2011, the agent was listed as being in phase II development ; in October 2012, the agent was in phase II development for hyperhidrosis. In March 2013, phase II trials were underway for migraine headaches. In March 2014, the drug was listed as being in phase II development for hyperhidrosis and migraine headache; also as phase I development for an unidentified indication. In October 2012, the agent was listed as being in preclinical development for acne. In March 2011, the company was seeking to outlicense the drug ; in October 2012, this was still the case.

Revance is also developing RT-001 for cosmetic purposes, not covered by this record.

The company was previously investigating RT-001 for the potential treatment of plantar fasciitis ; however, no further development had been reported since December 2009.

RT-001, Revance Therapeutics DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date

Return to Table of Contents

Company	Indication	Country	Development Status	Date
Revance Therapeutics Inc	Hyperhidrosis	Canada	Phase 2 Clinical	31-Jan-2007
Revance Therapeutics Inc	Hyperhidrosis	US	Phase 2 Clinical	31-Jan-2007
Revance Therapeutics Inc	Migraine	US	Phase 2 Clinical	25-Mar-2013
Revance Therapeutics Inc	Unidentified indication	US	Phase 1 Clinical	24-Mar-2014
Revance Therapeutics Inc	Acne	US	Discovery	03-Mar-2011
Revance Therapeutics Inc	Musculoskeletal system inflammation	US	No Development Reported	30-Jun-2011

RT-001, Revance Therapeutics DRUG NAMES

Names	Type
RT-001, Revance Therapeutics	Research Code
BoNTA protein (topical gel, hyperhidrosis), Revance	

RT-001, Revance Therapeutics CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Aging											
0	0	0	2	0	0	0	0	0	0	0	2

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	2	0	1	0	0	0	0	0	3

Phase Definitions

Phase 3 Clinical
Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical
Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Return to Table of Contents

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

RT-001, Revance Therapeutics DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Revance Therapeutics Inc	1	0	3	0	4
Hospira Inc	1	0	0	0	1
List Biological Laboratories Inc	1	0	0	0	1
American Peptide Co	1	0	0	0	1
Valeant Pharmaceuticals International Inc	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart

Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	3	0	3
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

PATENTS

Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Revance Therapeutics Inc	3	0	3
Individual	1	0	1
Essentia Biosystems Inc	1	0	1
Valeant Pharmaceuticals International Inc	0	1	1
Duoject Medical Systems Inc	1	0	1

Return to Table of Contents

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Delivery device	1

Return to Table of Contents

RT-002

RT-002 SNAPSHOT

Drug Name	RT-002
Key Synonyms	
Originator Company	Revance Therapeutics Inc
Active Companies	Revance Therapeutics Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	Acetylcholine receptor antagonist;Botulinum toxin A stimulator
Other Actions	Neuromuscular blocking agent
Technologies	Injectable formulation;Biological therapeutic;Parenteral formulation unspecified;Peptide;Toxin
Last Change Date	14-Nov-2014

RT-002 DEVELOPMENT PROFILE

SUMMARY

Revance Therapeutics is investigating RT-002, as an injectable formulation of botulinum toxin type A (BoNTA) protein, delivered using the company's TransMTS peptide technology, for the potential treatment of an unidentified indication. In March 2014, the therapy was listed as being in preclinical development.

In November 2014, the company confirmed plans to initiate phase II trials in 2014 for glabellar lines. This indication is not covered by this record .

RT-002 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Revance Therapeutics Inc	Unidentified indication	US	Discovery	24-Mar-2014

RT-002 DRUG NAMES

Names	Type
BoNTA protein (injectable, unidentified indication), Revance	
RT-002	Research Code

Return to Table of Contents

RT-002 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Revance Therapeutics Inc	1	0	2	0	3
List Biological Laboratories Inc	1	0	0	0	1
American Peptide Co	1	0	0	0	1
Valeant Pharmaceuticals International Inc	0	0	1	0	1

Return to Table of Contents

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	2	0	2
Drug - Development/Commercialization License	1	0	1

Return to Table of Contents

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:
http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

Return to Table of Contents